In a study among oncology patients with moderate to severe iron deficiency anaemia, ferric carboxymaltose (FCM) administration resulted in a significant reduction in the transfusion requirements with a sustainable increase of Hb level (22). This evidence concerns the gene GSTM1 and Iron deficiency anemia.